EyePoint, Inc. (EYPT) Presents at UBS World Biopharma Convention 2026 Transcript

0


Q3: 2026-11-12 Earnings Abstract

EPS of -$1.07 misses by $0.14

 | Income of $756.00K (-21.74% Y/Y) beats by $522.92K

EyePoint, Inc. (EYPT) UBS World Biopharma Convention 2026 November 17, 2026 3:40 AM EST

Firm Contributors

George Elston – Government VP & CFO
Jay Duker – President, CEO & Director

Convention Name Contributors

Alice Nettleton

Presentation

Alice Nettleton

Good morning, everybody. Welcome to the subsequent session on the UBS World Biopharma Convention. I am Alice Nettleton, one of many SMID Biotech analysts at UBS.

Completely satisfied to introduce the workforce from EyePoint. We have now Jay Duker, President and CEO; and in addition George Elston, Government VP and CFO. Welcome to each of you. Thanks a lot for becoming a member of us as we speak.

George Elston
Government VP & CFO

Thanks very a lot for having us.

Query-and-Reply Session

Alice Nettleton

So possibly simply to stage set, you have had some key Part III readouts this yr together with your drug, DURAVYU. Maybe simply type of present a abstract of the place you are at, in the mean time and what traders can stay up for.

Jay Duker
President, CEO & Director

Certain. And simply to offer a bit of little bit of background, DURAVYU is the vorolanib intravitreal insert. Vorolanib is a small molecule tyrosine kinase inhibitor that has exercise towards all of the VEGF receptors in addition to PDGF and JAK1. We’re finding out it in 2 main retinal indications, moist age-related macular degeneration and diabetic macular edema. We just lately reported the highest line Part III outcomes from the moist AMD trials. We did 2 trials. They have been known as LUGANO and LUCIA. And sadly, we did not make the first endpoint in both trial. The first endpoint was non-inferiority change in visible acuity within the DURAVYU arm in comparison with on-label 2-milligram Eylea. And whereas the secondary endpoints within the trials, we imagine, have been fairly good, we weren’t noninferior.

So this present day, we have now 2 totally enrolled diabetic macular edema trials. They’re

Leave a Reply

Your email address will not be published. Required fields are marked *